Organon posts Q4 net loss of $205 million on $301 million goodwill impairment
Organon reported a fourth-quarter 2025 net loss of $205 million, or $0.79 per diluted share, compared with net income of $109 million, or $0.42 per share, a year earlier. The loss includes a non-cash $301 million goodwill impairment, and full-year revenue fell 3% to $6.2 billion. The company expects 2026 revenue of about $6.2 billion and Adjusted EBITDA of about $1.9 billion, both in line with 2025, while an Audit Committee review of the timing of biosimilar purchases from a supplier is underway.
Key points
- Q4 2025 revenue was $1.507 billion, down 5% from $1.592 billion, and reported gross margin fell to 49.2% from 56.3%.
- Full-year 2025 diluted EPS was $0.72, down from $3.33; non-GAAP Adjusted diluted EPS was $3.66, down from $4.11.
- The Audit Committee review began after information was brought to its attention on February 11, 2026; the company has not determined that anything inappropriate occurred.
- The Board declared a quarterly dividend of $0.02 per share, payable March 12, 2026, to holders of record on February 23, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 12, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.